Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.

Abstract

A total of 76 patients discontinued treatment with didanosine plus hydroxyurea after 1 year of maintenance therapy. The greatest human immunodeficiency virus (HIV)-RNA rebounds were seen in 10 patients harboring an L74V mutation, and the presence of viruses with this mutation rapidly waned. In contrast, viral rebounds were significantly less pronounced (P < 0.01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo.

• Authors: Carmen de Mendoza, Ellen Paxinos, Pablo Barreiro, Nuria Camino, Marina Núñez, Vincent Soriano
• Journal: Journal of clinical microbiology (J Clin Microbiol) Vol. 42 Issue 2 Pg. 862-6 (Feb 2004) ISSN: 0095-1137 [Print] United States
• PMID: 14766874 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• RNA, Viral
• Didanosine
• Thymidine
• Hydroxyurea

Topics

• Acquired Immunodeficiency Syndrome (drug therapy, immunology)
• Amino Acid Substitution
• Anti-HIV Agents (therapeutic use)
• CD4 Lymphocyte Count
• Didanosine (therapeutic use)
• Female
• Genotype
• HIV (genetics)
• Humans
• Hydroxyurea (therapeutic use)
• Male
• Mutagenesis, Site-Directed
• Mutation
• RNA, Viral (genetics, isolation & purification)
• Thymidine (genetics)
• Time Factors
• Viral Load